Boris Hadaschik

🚨🚨Prostate and UREthra on MRI (PURE-MRI): Try to contour (outline) the prostate and urethra on MRI for 1 patient After everyone is done, we will enable the “answer key” And you help us learn how to help doctors and AI do better Sign up here: redcap.link/PURE-MRI 🙏🏼

This study compares two cutting-edge PET radiotracers, 68Ga-NeoB and 68Ga-PSMA-R2, in detecting biochemically recurrent prostate cancer. Results show 68Ga-NeoB outperforms in detecting metastases at lower PSA levels, offering a promising alternative for molecular imaging and treatment. #ReadNow details on UroToday > bit.ly/4ey4pUO @HeyingDuan @beingDrGuido @JournalofNucMed

A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇👇👇👇👇👇👇👇 sciencedirect.com/science/articl… The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking. The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting. The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer. Our Thanks to all authors: @Silke_Gillessen @fabioturco92 @Prof_IanD @drjefstathiou Karim Fizazi @Prof_Nick_James Neal Shore Eric Small Matthew Smith @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims Emmanuel S. Antonarakis Ana Aparicio Andrew J. Armstrong Diogo Assed Bastos Gerhardt Attard Karol Axcrona Mouna Ayadi Himisha Beltran @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti Muhammad Bulbul Consuelo Buttigliero Orazio Caffo @cdanicas @Ecastromarcos Heather H. Cheng Kim N. Chi Caroline S. Clarke Noel Clarke Johann S. de Bono @mdesantis234 @nachoduranm @EfstathiouEleni Onyeanunam N. Ekeke Tamer I.H. El Nahas @drlouiseemmett @stefanofanti4 Omolara A. Fatiregun Felix Y. Feng Peter C.C. Fong @fontev1 @Nicola_Fossati Daniel J. George @marty_gleave Gwenaelle Gravis Susan Halabi Daniel Heinrich @ProfKHerrmann @DrMHofman Thomas A. Hope Lisa G. Horvath Maha H.A. Hussain @BarbaraJereczek Robert J. Jones Anthony M. Joshua @ravikanesvaran Daniel Keizman @FacsRaja Gero Kramer @LoebStacy Brandon A. Mahal Fernando C. Maluf 75 76, @quimmateo David Matheson 78, Mika P. Matikainen 79, Ray McDermott 80, @DrRanaMcKay Niven Mehra 82, @amerseburger @CaPsurvivorship , Michael J. Morris 85, Hind Mrabti 86, Deborah Mukherji @declangmurphy Vedang Murthy Shingai B.A. Mutambirwa @DrPaulNguyen William K. Oh @piet_ost Joe M. O’Sullivan Anwar R. Padhani Chris Parker Darren M.C. Poon Colin C. Pritchard Danny M Rabah Dana Rathkopf Robert E. Reiter Raphaele Renard-Penna Charles J. Ryan Fred Saad Juan Pablo Sade Shahneen Sandhu Oliver A. Sartor Edward Schaeffer Howard I. Scher Nima Sharifi Iwona A. Skoneczna Howard R. Soule @DrSpratticus Sandy Srinivas @cnsternberg Hiroyoshi Suzuki Mary-Ellen Taplin Camilla Thellenberg-Karlsson Derya Tilki Levent N. Türkeri Hiroji Uemura @DrYukselUrun Claire L. Vale Neha Vapiwala Jochen Walz Kosj Yamoah Dingwei Ye Evan Y. Yu Almudena Zapatero @AOmlin

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial out on @JCO_ASCO The CheckMate 914 ♟️trial is a phase III study that evaluated the efficacy of adjuvant nivolumab🧪 monotherapy (part B) versus placebo in patients with localized renal cell carcinoma (RCC) at high risk of recurrence after nephrectomy. #KidneyCancer In this randomized trial of 825 patients, the primary endpoint of disease-free survival (DFS) per blinded independent central review (BICR) was not met, with a hazard ratio (HR) of 0.87 (95% CI, 0.62 to 1.21; P = .40). Although the 18-month DFS rates were slightly higher in the nivolumab group (78.4% vs. 75.4% for placebo), the difference was not statistically significant. Adverse events, particularly grade 3-4 events, were more common with nivolumab plus ipilimumab, leading to higher treatment discontinuation rates. Overall, the study did not demonstrate a DFS benefit for nivolumab in this patient population. ascopubs.org/doi/full/10.12… @motzermd @YoshihikoTomita @HernanJCutuli @grimm_mo @JeffreyCGoh1 @BrianShuch @ViktorGruenwald #OncoAlertAF @nataliagandur @acampsmalea @BiagioRicciutMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @lungoncdoc @bavilima @realbowtiedoc @Erman_Akkus @DrFMartinelli @Lucarecco @heinrich_kat @niklas_kluemper